PMID- 25561764
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150106
LR  - 20200929
IS  - 1000-9604 (Print)
IS  - 1993-0631 (Electronic)
IS  - 1000-9604 (Linking)
VI  - 26
IP  - 6
DP  - 2014 Dec
TI  - Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical 
      significance.
PG  - 669-77
LID - 10.3978/j.issn.1000-9604.2014.12.04 [doi]
AB  - OBJECTIVE: Vascular-targeted therapy is gradually becoming more appealing for 
      patients with lung cancer. It is unclear whether vascular endothelial growth 
      factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1) can be biomarkers for 
      clinical treatment. We aimed to investigate the expression levels of VEGFR2 and 
      NRP-1 in human non-small cell lung cancer (NSCLC) and their clinical significance 
      by observing patient prognosis. METHODS: VEGFR2 and NRP-1 were assessed by 
      immunohistochemistry (IHC) in 40 patients with NSCLC and in 10 patients with 
      benign lesions of lung; kinase insert domain receptor (KDR) and NRP-1 copy number 
      gain (CNG) was assessed by fluorescence in situ hybridization (FISH). The 
      distributions of overall survival (OS) and progression-free survival (PFS) were 
      estimated using the Kaplan-Meier method and compared between groups by log-rank 
      test. RESULTS: Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 
      55%, respectively. KDR and NRP-1 CNG (+) were detected in 32.5% and 30% of 
      tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were 
      significantly different than in the control tissue (chi(2)=11.22, P=0.001; 
      chi(2)=9.82, P=0.001, respectively); similar results were obtained using CNGs 
      (chi(2)=4.39, P=0.036; chi(2)=3.95, P=0.046, respectively). Statistically significant 
      correlations were observed with histological grade, clinical TNM stage and the 
      lymph node status (P<0.05), but not age, gender or pathology type (P>0.05). 
      VEGFR2 showed a strong correlation with NRP-1 (Rs=0.68, P=0.00); similar results 
      were observed with KDR and NRP-1 CNG (Rs=0.32, P=0.04). Significant differences 
      in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and 
      those with lower expression (P<0.05). CONCLUSIONS: According to these data, 
      VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a 
      key role in NSCLC occurrence, development and metastasis and are associated with 
      patient prognosis (P<0.05 for OS and PFS). This information will be beneficial 
      for clinical anti-angiogenic treatment in NSCLC.
FAU - Ding, Manhua
AU  - Ding M
AD  - 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou 
      Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, 
      Lianyungang First People's Hospital, Lianyungang 222002, China.
FAU - Liu, Liang
AU  - Liu L
AD  - 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou 
      Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, 
      Lianyungang First People's Hospital, Lianyungang 222002, China.
FAU - Hu, Chengxi
AU  - Hu C
AD  - 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou 
      Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, 
      Lianyungang First People's Hospital, Lianyungang 222002, China.
FAU - Liu, Yi
AU  - Liu Y
AD  - 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou 
      Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, 
      Lianyungang First People's Hospital, Lianyungang 222002, China.
FAU - Qiao, Yun
AU  - Qiao Y
AD  - 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou 
      Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, 
      Lianyungang First People's Hospital, Lianyungang 222002, China.
FAU - Jiang, Xiaodong
AU  - Jiang X
AD  - 1 Xuzhou Medical College, Xuzhou 221006, China ; 2 Department of Oncology, Xuzhou 
      Cancer Hospital, Xuzhou 221005, China ; 3 Department of Radiotherapy Oncology, 
      Lianyungang First People's Hospital, Lianyungang 222002, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Cancer Res
JT  - Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
JID - 9315242
PMC - PMC4279211
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - fluorescence in situ hybridization (FISH)
OT  - neuropilin-1 (NRP-1)
OT  - vascular endothelial growth factor receptor 2 (VEGFR2)
EDAT- 2015/01/07 06:00
MHDA- 2015/01/07 06:01
PMCR- 2014/12/01
CRDT- 2015/01/07 06:00
PHST- 2014/10/03 00:00 [received]
PHST- 2014/11/18 00:00 [accepted]
PHST- 2015/01/07 06:00 [entrez]
PHST- 2015/01/07 06:00 [pubmed]
PHST- 2015/01/07 06:01 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
AID - cjcr-26-06-669 [pii]
AID - 10.3978/j.issn.1000-9604.2014.12.04 [doi]
PST - ppublish
SO  - Chin J Cancer Res. 2014 Dec;26(6):669-77. doi: 
      10.3978/j.issn.1000-9604.2014.12.04.